Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008


Toronto Stock Exchange Symbol: MS

- US$10 million received based on the positive review of interim

analysis for international pivotal multiple sclerosis trial -

EDMONTON, Sept. 22 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.

To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.

"We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, President and CEO of BioMS Medical. "We look forward to completing the MAESTRO-01 trial and reviewing the complete data set in the second half of 2009."

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 Publicis Healthcare Communications Group ... the organization has won a total of 20 awards ... LifeBrands was honored with a Silver Award and 11 ... eight Awards of Excellence. , The Annual Rx ... and promotion. The Awards provide a forum for the ...
(Date:11/26/2014)... November 26, 2014 In keeping with ... customers a bevy of last-minute Thanksgiving savings. The company ... offers across all product lines this holiday weekend as ... Thanksgiving, Black Friday, and Cyber Monday are right around ... thanks to both loyal customers and those looking to ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology Graduate ... community to the UMBC campus for a discussion on ... Society, will take place from 9 a.m. to 4 ... discussion, presentations and workshops, the free symposium will highlight ... in the industry and the future of protein research. ...
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer ... recently participated in the American Urology Association’s (AUA) ... Key opinion leaders in urology presented on the ... renal masses while attendees had the opportunity to ... hands-on labs. Attendees at the Los Angeles, CA ...
Breaking Biology Technology:Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... ,, A review of products for signal ... Activation of Signal Transduction Pathways with,PathDetect ... Mary Buchanan Chao-Feng Zheng ,Stratagene , ... such as,growth, differentiation, and coordination of cellular activities. ...
... streamlined and reliable method to obtain high-quality ... Basehore ,Stratagene , The StrataPrep ... quick, and reliable purification of bacteriophage single-stranded ... phage lysate exceeds the yield,obtained with the ...
... Preadipocytes and Differentiated Adipocytes ,,, A ... , Yuan-Di C. Halvorsen ,Zen-Bio, Inc. , ... , Regis Saladin , Ligand Pharmaceuticals ... , Stratagene introduces new tools to facilitate ...
Cached Biology Technology:Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 2Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 3Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 4Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 5Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 6Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 7Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 8Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 9Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 10Purified Single-Stranded M13 DNA for Automated Sequencing 2Purified Single-Stranded M13 DNA for Automated Sequencing 3Human Primary Preadipocytes and Differentiated Adipocytes 2Human Primary Preadipocytes and Differentiated Adipocytes 3Human Primary Preadipocytes and Differentiated Adipocytes 4Human Primary Preadipocytes and Differentiated Adipocytes 5Human Primary Preadipocytes and Differentiated Adipocytes 6
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... have believed that eating large amounts of protein made it ... the winner of five consecutive Olympic wrestling championships in the ... he built his crushing strength in part by consuming 20 ... go to such extremes, but Milo,s legacy survives in the ...
... cells, which make up 45 percent of blood, normally take ... side. But they can sometimes deform into an asymmetrical slipper ... explore how fluid flow might be responsible for this deformation, ... flow. The insights could help understand the mechanisms involved in ...
... 26, 2009 Results of an important new study ... at the time of cataract surgery increases a nutritional ... the development and/or progression of age-related macular degeneration (AMD). ... from the Macular Pigment Research Group at the Waterford ...
Cached Biology News:Moderate amounts of protein per meal found best for building muscle 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 3Blue light-filtering increases macular pigment, may protect against age-related vision loss 4